Neuroscience researchers at Wayne State University published a review article that confirms the usefulness of neurofilament light (NfL) blood levels to predict the likelihood and rate of progression of neurodegeneration in Alzheimer's disease. The review article, 'The Potential of Blood Neurofilament Light as a Marker of Neurodegeneration in Alzheimer's disease,' is published in the journal Brain.
," Damoiseaux said."It could be especially useful in persons who show Alzheimer's pathology but are at present cognitively unimpaired, or in people who are highly likely to develop Alzheimer's disease due to having the APOE ε4 allele or higher Aβ load."
Longitudinal studies also consistently found significant relationships between blood NfL and atrophy in brain regions vulnerable to Alzheimer's disease pathology."We found that an increase in blood NfL may precede Alzheimer's disease-related changes in cortical atrophy and may be elevated in the preclinical stages of Alzheimer's disease," Damoiseaux said.
The review of the cross-sectional and longitudinal literature showed that blood NfL levels consistently predicted the severity of atrophy andThe work by Jung and Damoiseaux highlights that blood NfL is a useful prognostic marker for predicting the progression of neurodegeneration, as well as being a useful marker to assess the risk that a cognitively unimpaired person with a higher risk for Alzheimer's disease will show abnormal changes in brain structure and function.
Jung warns that there are still knowledge gaps to be filled for the appropriate use of blood NfL as a biomarker."We need more studies on how blood NfL is related to different aspects of neuronal damage," she said,"and the field should seek to learn more about potential factors that may affect the NfL concentration in the blood."
Jung is a doctoral student in the Behavioral and Cognitive Neuroscience program and a trainee at WSU's Institute of Gerontology. Damoiseaux is an associate professor in the Institute of Gerontology and the Department of Psychology.Youjin Jung et al, The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer's disease,
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Aligning Rhythms, Defying Alzheimer's: Intermittent Fasting's Role in Combating Alzheimer's Disease NeurodegenerationThought Leaders Dr.
Read more »
New blood test gives high accuracy screen for Alzheimer's diseaseA new blood test called p-tau217 shows promise as an Alzheimer's disease biomarker, and when used in a two-step workflow very high accuracy to either identify or exclude brain amyloidosis, the most important and earliest pathology. That is an innovation now presented by researchers at the University of Gothenburg, together with colleagues at University of Lund and in Montreal, Canada.
Read more »
Alzheimer's screening just got easier, more accurate with new blood testA new blood test called p-tau217 shows promise as an Alzheimer's disease biomarker, and when used in a two-step workflow very high accuracy to either identify or exclude brain amyloidosis, the most important and earliest pathology.
Read more »
Discoveries on memory mechanisms could unlock new therapies for Alzheimer's and other brain diseasesScientists at the University of Colorado Anschutz Medical Campus have made a 'paradigm shifting' discovery on the mechanisms required for learning and memory that could lead to new therapies for Alzheimer's disease and potentially Down syndrome. The study was published in the journal Nature.
Read more »
Scientists reverse Alzheimer's plaque formation in animal models by boosting activity of key ion channelLosing the activity of a key ion channel in the brain may contribute to the buildup of a devastating and toxic protein responsible for the clumps of plaque that accumulate in Alzheimer's disease, a team of neurobiologists in China has found.
Read more »
New study finds genetic factor fends off Alzheimer's and Parkinson'sAbout one in every five people carries a version of a gene that—although largely unsung—appears to confer protection against both Alzheimer's disease and Parkinson's disease, Stanford Medicine investigators and their colleagues have learned. These lucky people may someday benefit all the more from a vaccine that could slow or stall the progression of these two most common neurodegenerative conditions.
Read more »